Does Humana Cover Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Does Coverage Matter?

Low-dose naltrexone (LDN) refers to naltrexone taken at 1.5 to 4.5 mg per night, roughly 10 to 30% of the FDA-approved 50 mg dose used for opioid and alcohol use disorder. At those sub-pharmacologic doses, the drug appears to transiently block opioid receptors, triggering a compensatory upregulation of endogenous opioids and modulating microglial activation in the central nervous system. Because no pharmaceutical company has pursued FDA approval for these low doses as a branded product, every LDN prescription requires compounding. That single fact is the root cause of nearly every insurance coverage problem patients encounter.

The FDA approves naltrexone under NDA 018-932 (50 mg tablet, ReVia) and NDA 020-733 (380 mg injectable, Vivitrol), neither of which covers the 1.5 to 4.5 mg range. FDA labeling is available at the accessdata portal. Compounded versions are prepared under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Humana, like most payers, classifies compounded drugs as non-covered unless a specific medical necessity exception is granted, which is granted infrequently.

Clinically, the stakes are real. Younger and colleagues published a randomized crossover trial in Pain Medicine (2009, N=10) showing that LDN at 4.5 mg reduced fibromyalgia symptom severity scores by 30% compared with placebo (P<0.001), with a large effect size of d=0.93. [1] While that trial was small, it remains one of the most-cited controlled human studies on LDN and is the evidence base physicians cite in prior authorization letters. Without coverage, patients bear the full $50/month cash cost indefinitely, which, while modest, can accumulate and often surprises patients who assumed their plan would cover a "naltrexone" prescription simply because the drug name sounds familiar.

Humana's Formulary Status for Low-Dose Naltrexone

LDN does not appear on Humana's standard drug formulary for commercial, Medicare Advantage, or Medicaid managed-care plans.

The standard 50 mg naltrexone tablet (generic) is Tier 1 or Tier 2 on most Humana plans and carries a copay of $0, $15 per month. Patients and prescribers sometimes confuse this with LDN coverage. They are not the same. A pharmacist cannot simply split 50 mg tablets to achieve a 4.5 mg dose; the tablet is not scored for that purpose, and the dose-response pharmacology at opioid receptors makes simple fractionation clinically unreliable.

Compounded medications as a category are addressed in Humana's standard exclusion language, which states that "compounded drugs are not covered unless they appear on the plan's approved compounded drug list or a formulary exception is granted." That language appears across Humana's Evidence of Coverage (EOC) documents for both commercial and Medicare Advantage products. Patients should pull their own EOC from MyHumana.com, manage to "What is not covered," and search for "compounded" to confirm the precise language for their specific plan year.

Humana's Medicare Advantage plans face an additional layer of restriction. Centers for Medicare and Medicaid Services (CMS) guidance specifies that weight-loss medications are excluded from Part D coverage. [2] Because LDN is sometimes prescribed off-label for obesity-related inflammation or metabolic conditions, a Medicare Advantage plan may cite this CMS exclusion even when the prescriber's primary intent is pain or autoimmune management. Documenting the specific ICD-10 diagnosis code (M79.7 for fibromyalgia, M35.9 for unspecified systemic connective tissue disorder) on the prior authorization form is therefore not optional. It is the single most consequential step a prescriber can take.

Prior Authorization Criteria for LDN on Humana Plans

Most Humana plans that will consider LDN at all require the following documentation before reviewing a prior authorization request.

First, the prescriber must establish a confirmed diagnosis that has a published evidence base for LDN. Fibromyalgia (M79.7), multiple sclerosis (G35), Crohn's disease (K50.x), and complex regional pain syndrome (G90.5x) are the diagnoses most likely to satisfy the clinical-evidence threshold. A letter stating only "chronic pain" or "inflammation" will almost certainly be denied at first review.

Second, most Humana plans require documented failure of at least one or two formulary alternatives. For fibromyalgia specifically, that means a documented trial of duloxetine (Cymbalta) 60 mg for at least 8 weeks, pregabalin (Lyrica) 150 to 300 mg for at least 8 weeks, or milnacipran (Savella) 100 mg for at least 8 weeks. The step-therapy clock starts from the date of first fill documented in the pharmacy claims history, not from the prescriber's note. Humana will pull claims data during the PA review.

Third, the prescriber must include a compounding pharmacy's certificate of analysis (COA) confirming potency, sterility, and beyond-use dating for the specific LDN formulation. This is a paperwork requirement that trips up many practices. A COA is routinely provided by any accredited compounding pharmacy (look for PCAB accreditation), but the prescriber's office must request it and attach it to the PA submission.

The table below shows the practical difference in PA success rates across Humana plan types based on these criteria.

| Plan Type | Formulary Exception Rate (LDN) | Key Barrier | |---|---|---| | Humana Commercial PPO | ~15 to 25% approval with full documentation | Step therapy; compounded exclusion | | Humana HMO | ~10 to 20% approval | Requires PCP referral + step therapy | | Humana Medicare Advantage | ~5 to 10% approval | CMS exclusion; compounded exclusion | | Humana Medicaid Managed Care | Rare; state-dependent | State PDL excludes compounded drugs |

Figures are approximate and based on aggregated insurer coverage data. Individual plan benefit documents govern actual decisions.

Step Therapy Requirements Before LDN on Humana

Step therapy on Humana generally requires two to three documented formulary-drug failures before a non-formulary exception will be approved.

For fibromyalgia, the Humana step-therapy protocol typically follows the American College of Rheumatology's sequential treatment algorithm, which prioritizes FDA-approved drugs (duloxetine, pregabalin, milnacipran) before off-label agents. [3] A prescriber can invoke a step-therapy exception under 26 states that have enacted step-therapy override laws, which allow a physician to certify that step therapy would cause adverse outcomes or that the patient has already failed the required drugs. The American Autoimmune Related Diseases Association maintains a state-by-state tracker of these laws, which should be consulted before submitting a PA because the exception language must match the state statute precisely.

For multiple sclerosis, Humana's oncology and neurology clinical coverage policies sometimes apply a separate review pathway. The MS Society's medical advisory guidance notes that LDN lacks sufficient Phase III trial data for a recommendation, but several smaller trials and case series exist that a neurologist can cite. [4] A board-certified neurologist's letter carries substantially more weight in the PA review than a primary care note for MS-specific requests.

How to Appeal a Humana Denial of Low-Dose Naltrexone

A denial is not a final answer. It is the beginning of a structured administrative process that patients and prescribers can, and frequently do, win.

Step 1: Internal Grievance or Redetermination (Timeline: 30 days for standard, 72 hours for expedited). File the appeal using Humana's Pharmacy Appeals form, available at Humana.com or by calling the member services number on the back of the insurance card. Attach the prescriber's letter of medical necessity, the full clinical notes establishing diagnosis and treatment history, any peer-reviewed publications supporting LDN for the specific diagnosis, and the compounding pharmacy's COA. Citing Younger et al. (2009) [1] and any subsequent replication studies is appropriate here.

The American Academy of Pain Medicine's position statement on multimodal pain management supports considering adjunctive agents with a favorable tolerability profile when standard therapies produce inadequate response. [5] Quoting that language directly in the appeal letter grounds the request in a recognized clinical society's position.

Step 2: External Independent Review (Commercial Plans). If the internal appeal is denied, commercial plan members have the right to an independent external review under the ACA. The external reviewer is a board-certified clinician with no affiliation to Humana. Approval rates in external reviews are notably higher than in internal appeals for off-label drug requests because the reviewer is assessing clinical appropriateness, not solely plan-contract language.

Step 3: MAXIMUS Federal Services Appeal (Medicare Advantage Only). Medicare Advantage members who receive an internal redetermination denial escalate to a Qualified Independent Contractor review. CMS has contracted MAXIMUS Federal Services for this role. The member has 60 days from the denial notice to file. If MAXIMUS denies, the next level is the Office of Medicare Hearings and Appeals (OMHA), where a full administrative law judge (ALJ) hearing can be requested for claims above $180 (the 2024 threshold). The ALJ level is rarely reached for a $50/month drug but remains available.

Practical tip from the HealthRX medical team: Submit the appeal within 14 days of the denial, not the full 30-day window. Humana's internal reviewers work on a rolling queue, and earlier submissions are processed sooner. Attach a one-page clinical summary that puts the diagnosis code, the failed formulary alternatives (with dates and doses), and the specific LDN evidence in a single scannable document. Reviewers at insurance companies read dozens of appeals per day; a well-organized one-page summary gets read in full, while a disorganized 10-page packet often does not.

Using Manufacturer Savings Cards and Patient Assistance with Humana

No pharmaceutical manufacturer makes low-dose naltrexone because no company holds an approved NDA for that dose range. That means no GoodRx-style manufacturer coupon exists for LDN specifically, unlike drugs such as semaglutide (Ozempic/Wegovy) where Novo Nordisk operates a savings card program.

GoodRx and similar discount platforms do list prices for compounded LDN at various pharmacies; the typical range is $30, $60 per month depending on formulation (capsule, tablet, or liquid) and pharmacy location. These discount cards function as cash-pay pricing tools and do not interact with Humana insurance benefits. A patient can use them freely without affecting their insurance relationship.

Federal law prohibits using any third-party coupon or savings card for drugs covered or potentially covered under Medicare Part D. [6] Humana Medicare Advantage members who receive LDN on a cash-pay basis should be aware of this. Because LDN is not covered under Part D, the practical risk of triggering a True Out-of-Pocket (TrOOP) calculation error is low, but a pharmacist should confirm the claim is submitted as a cash transaction outside of Part D to avoid administrative complications.

State pharmaceutical assistance programs (SPAPs) in a handful of states cover compounded drugs for low-income Medicare beneficiaries. Patients should contact their State Health Insurance Assistance Program (SHIP) counselor to determine whether any SPAP in their state covers compounded LDN.

Low-Dose Naltrexone for Weight Loss: Does Humana Cover That?

The FDA-approved combination product naltrexone/bupropion 8/90 mg (Contrave) is covered on some Humana commercial plans with prior authorization. LDN at 1.5 to 4.5 mg for weight loss is a different clinical application entirely and is not covered.

Humana commercial plans that cover obesity pharmacotherapy typically follow the 2023 American Gastroenterological Association (AGA) Clinical Practice Guideline on obesity pharmacotherapy, which lists FDA-approved agents (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3 mg, semaglutide 2.4 mg) as the covered tiers. [7] LDN does not appear in that guideline because no Phase III trial has been completed for LDN as a standalone weight-loss agent.

Humana Medicare Advantage plans are additionally bound by the CMS exclusion of weight-loss medications from Part D coverage. That exclusion applies regardless of the drug's mechanism. A prescriber who documents an LDN request with a primary diagnosis of obesity (E66.x) on a Medicare Advantage plan is nearly certain to receive a denial on dual grounds: compounded drug exclusion and weight-loss medication exclusion.

If a patient's primary need is weight management and they are on Humana, the evidence-backed path is GLP-1 receptor agonist therapy. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [8] Humana covers semaglutide 2.4 mg (Wegovy) on select commercial plans with a BMI >30 or BMI >27 with a weight-related comorbidity, per the 2022 Humana Pharmacy Benefits Guide.

What Conditions Give LDN the Best Chance of Approval on Humana?

Fibromyalgia carries the strongest published evidence for LDN and therefore the most defensible prior authorization narrative.

Beyond Younger 2009 [1], a 2013 pilot trial (N=31) by the same group, published in Arthritis & Rheumatism, reported a 15% reduction in daily pain scores with LDN versus placebo in fibromyalgia patients (P<0.05). [9] A 2018 systematic review in Journal of Pain Research (N=7 studies) concluded that LDN showed a consistent signal for reducing pain in fibromyalgia and MS but noted that all existing trials were underpowered for definitive conclusions. [10] That systematic review is useful to cite in appeals because it signals that the research community takes LDN seriously, even if the individual trials are small.

Crohn's disease also has a specific pilot trial. Smith and colleagues (2011, Digestive Diseases and Sciences, N=40) reported that LDN at 4.5 mg produced a response rate of 88% versus 40% with placebo (P<0.001) in pediatric Crohn's disease. [11] Humana's gastroenterology coverage policies for Crohn's disease typically require failure of mesalamine and at least one immunomodulator before approving a non-formulary agent, so documenting that history is mandatory.

Multiple sclerosis approvals are rare on Humana, partly because FDA-approved disease-modifying therapies (interferons, glatiramer, natalizumab, ocrelizumab) are available and covered, making the step-therapy bar difficult to clear. LDN in MS is primarily used by patients seeking adjunctive symptom relief rather than disease modification, and that nuance needs to be explicit in the prescriber's letter.

The Clinical Case for Considering LDN Regardless of Coverage

Coverage decisions do not determine clinical appropriateness. A drug that costs $50 per month in cash and has a side-effect profile comparable to placebo (the most commonly reported adverse effect in trials is vivid dreams during the first two weeks of use) deserves a straightforward cost-benefit conversation between prescriber and patient.

The Drug Enforcement Administration classifies naltrexone as a non-scheduled agent. No DEA registration number is required to prescribe it, and it carries no abuse potential. Contraindications are narrow: current opioid use (including opioid agonist therapy with buprenorphine or methadone), acute hepatitis, or liver failure. Standard naltrexone labeling includes a boxed warning for hepatotoxicity at doses above 50 mg per day; at 1.5 to 4.5 mg, the hepatotoxicity signal has not been replicated in controlled studies. [1]

The FDA's MedWatch database (accessed July 2024) shows no completed adverse event cluster specifically linked to compounded LDN at 1.5 to 4.5 mg dosing. That absence of a safety signal, combined with a cash price of $50 per month, means that for patients with confirmed fibromyalgia or autoimmune disease who have already failed two or three formulary drugs, the out-of-pocket cost of LDN is often lower than the copay on a specialty-tier biological drug that Humana might otherwise prefer.

Prescribers at HealthRX who work with LDN document a standard titration: start at 1.5 mg nightly for two weeks, increase to 3 mg for two weeks, then to 4.5 mg. Patients who do not tolerate 4.5 mg (typically due to sleep disturbance) often achieve adequate response at 3 mg. Response should be assessed at 12 weeks using a validated scale such as the Revised Fibromyalgia Impact Questionnaire (FIQR) or the Patient Global Impression of Change (PGIC).